These findings underscore Gal-1 as a promising therapeutic target for addressing prostate cancer progression beyond drug resistance, enhancing the potential of inhibitors like LLS30 in treating advanced prostate cancer. This evidence concerns the gene LGALS1 and prostate carcinoma.